Abstract 139P
Background
The management of anal squamous cell carcinoma (ASCC) has yet to benefit from the progress of precision medicine. The few prognostic factors assessed to date are insufficient to accurately predict clinical outcomes. Patients with tumor resistant to chemoradiation therapy, or those experiencing localized recurrence after treatment, are subject to abdominoperineal resection (APR), an invasive procedure that significantly impairs quality of life. Genomic analyses could identify new prognostic biomarkers and potential avenues for targeted therapies.
Methods
We assessed the prognostic and theragnostic value of pathogenic variants identified in 571 cancer-related genes in surgical samples collected from a multicentric retrospective French cohort of 158 ASCC patients who underwent APR.
Results
Alterations in PI3K/AKT/mTOR (43%), chromatin remodeling (48%), and Notch pathways (22%) were frequent in HPV-positive tumors, while HPV-negative tumors (11%) often had variants in cell cycle regulation and genome integrity maintenance genes, like TP53 (59%) and TERT promoter mutations (47%). In patients with HPV-positive tumors, KMT2C (16%) and PIK3CA exon 9/20 pathogenic variants (22%) were associated with poor overall survival (Hazard Ratio (HR)KMT2C = 2.54, 95%CI = 1.25-5.17, p-value = 0.010; HRPIK3CA = 2.43, 95%CI = 1.3-4.56, p-value = 0.006), and progression-free survival (HRKMT2C = 3.38, 95%CI = 1.83-6.26, p-value < 0.001; HRPIK3CA = 1.81, 95%CI = 1.06-3.08, p-value = 0.029) in multivariate analyses. Alterations with theragnostic value in another cancer type (e.g., PIK3CAH1047R or loss-of-function variants in homologous repair genes) were detected in 43% of tumors.
Conclusions
PIK3CA exon 9/20 and KMT2C pathogenic variants are independent prognostic factors in patients with HPV-positive ASCC treated by APR. Importantly, the high prevalence of alterations with potential theragnostic value strongly supports the use of genomic profiling to allow patient enrollment in precision medicine clinical trials.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Fondation de France, Société Nationale Française de Gastroentérologie, Ligue Contre le Cancer.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract